Total
0
Shares
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay
CEO & Managing Director, Dr Steven Gourlay
Source: Steven Gourlay/LinkedIn
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Actinogen Medical (ACW) places its shares in a trading halt to finalise the details of an upcoming capital raising
  • The company’s shares will remain in the halt until November 25 or when more details are released, whichever occurs first
  • On November 9, Actinogen announced it had gained US Food and Drug Administration (FDA) approval to proceed with a clinical trial in patients with Fragile X Syndrome
  • Actinogen’s phase two trial will see around 50 patients with Fragile X be treated using Xanamem over a 12-week period
  • Shares in Actinogen last traded at 16 cents on November 22

Actinogen Medical (ACW) has placed its shares in a trading halt to finalise the details of an upcoming capital raising.

The company’s shares will remain in the halt until November 25 or when more details are released, whichever occurs first.

Actinogen is yet to disclose how much it intends to raise or what the funds will be used for once received.

On November 9, Actinogen announced it had gained US Food and Drug Administration (FDA) approval to proceed with a clinical trial in patients with Fragile X Syndrome.

Fragile X is caused by a change to one of the genes on the X chromosome, resulting in mild to severe intellectual disabilities.

While it affects both males and females, the latter tends to have milder symptoms.

Currently, there are no approved therapies with treatment including medications such as muscle relaxants, sedatives and cognition-enhancing medication.

Actinogen’s phase two trial will see around 50 patients with Fragile X be treated using Xanamem over a 12-week period.

Xanamem works by blocking the excess production of intracellular cortisol — the stress hormone — through the inhibition of the 11ß-HSD1 enzyme in the brain.

Results from the trial are expected in 2023.

Shares in Actinogen last traded at 16 cents on November 22. The company has a $268.3 million market cap.

ACW by the numbers
More From The Market Herald
Vection Technologies (ASX:VR1) - Managing Director, Gianmarco Biagi

" Vection Technologies (ASX:VR1) begins week in trading halt

Vection Technologies (VR1) has begun the week in a trading halt while it plans the details of an upcoming capital raising.
The Market Herald Video

" Week in review: Twiggy’s Tattarang backs Emyria’s cannabinoid, MDMA and magic mushroom trials

Welcome to the Market Herald Deal Room for this Friday, where we review the week in capital raising.
Matrix Composites and Engineering (ASX:MCE)

" Matrix Composites & Engineering (ASX:MCE) planning capital raise

Matrix Composites & Engineering (MCE) has entered into a trading halt while it plans the final details of an upcoming capital raise.
Firstwave Cloud Technology (ASX:FCT) - Executive Chairman, John Grant

" FirstWave Cloud Technology (ASX:FCT) halts trade on acquisition and cap raise

FirstWave Cloud Technology (FCT) has placed its shares in a trading halt, effective immediately.